Doravirine and Sofosbuvir and velpatasvir interaction

Doravirine and Sofosbuvir and velpatasvir: both prescribing labels mention this combination without an instruction to avoid it or change the dose.

Minor

Mentioned, no instruction to avoid. Worth knowing; rarely a reason to change anything on its own.

What the FDA labels say

From the Sofosbuvir and velpatasvir (Vosevi) label · effective 2025-07-14

Minor

Antiretrovirals: atazanavir lopinavir ↑ voxilaprevir Coadministration of VOSEVI with atazanavir- or lopinavir-containing regimens is not recommended. tipranavir/ritonavir ↓ sofosbuvir ↓ velpatasvir Coadministration is not recommended.

Drug interactionsby drug classView label on DailyMed

From the Doravirine (PIFELTRO) label · effective 2026-07-08

No interaction

…clinically significant changes in concentration were observed for doravirine when co-administered with the following agents: dolutegravir, TDF, lamivudine, elbasvir and grazoprevir, ledipasvir and sofosbuvir, ritonavir, ketoconazole, aluminum hydroxide/magnesium hydroxide/simethicone containing antacid, pantoprazole, and methadone [see Clinical Pharmacology (12.3) ].

Drug interactionsnames Sofosbuvir and velpatasvirView label on DailyMed
No interaction

…clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3) ] .

Drug interactionsnames Sofosbuvir and velpatasvirView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.